Celselect Slides 2.0
HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Celselect Slides 2.0 to enhance rare cell and circulating tumor cell (CTC) capture. Compatible with Bio-Rad’s Genesis Cell Isolation System, the latest version of Celselect Slides enables the processing of greater volumes of liquid biopsy samples and offers the ability to capture and recover a greater number of CTCs for enumeration or use in downstream applications.
The Genesis Cell Isolation System provides researchers with unbiased size-based microfluidic cell selection to gently and efficiently capture a wide range of CTCs and other rare cells from liquid biopsy samples such as blood in one benchtop solution. The latest version of Celselect Slides allows researchers to load 2.5x more sample per slide compared to Celselect Slides 1.0, increasing the sample volume from 4 ml to 10 ml. The number of microchambers in which CTCs are captured has also increased, from 56,400 in the version 1.0 slides to 140,800 in the version 2.0 slides. The Genesis System’s two-bay design accepts two Celselect Slides that can be run independently, now permitting a total volume of 20 ml of sample to be processed at one time. Bio-Rad’s new slide design is also compatible with full standard blood tube runs (~8 ml), allowing seamless integration into researchers’ existing workflows.
The increased volume of liquid biopsy sample accepted by the Genesis Cell Isolation System will allow researchers to process a larger amount of sample in a single run, improving the efficiency of CTC capture. This will increase the number of viable CTCs captured for immunofluorescence applications such as enumeration and identification of various CTC types, for downstream analyses such as next-generation sequencing or Droplet Digital™ PCR, or for sub-cultivation.
"CTCs are rare — as low as only 1–10 can be found per milliliter of blood — however, CTC enumeration and analysis offers valuable insight into tumor heterogeneity and disease progression,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Building on the capabilities of Celselect Slides 1.0, we're continuing to improve the efficiency of rare CTC enrichment, enumeration, and recovery to accelerate cancer research workflows. This launch reflects the expansion of our technological capabilities and our commitment to bringing novel solutions to researchers to improve our understanding of cancer and inform research programs."
To learn more about Bio-Rad’s Genesis System and Celselect Slides technology, visit bio-rad.com/genesis-system.
BIO-RAD, CELSELECT SLIDES, DROPLET DIGITAL, and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications
Dr. Maria Spyrou
+44 (0) 7707 049 640
maria.spyrou@zymecommunications.com